Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
11.84
-1.25 (-9.59%)
At close: Feb 12, 2026, 4:00 PM EST
11.78
-0.06 (-0.46%)
Pre-market: Feb 13, 2026, 6:57 AM EST
Arvinas Revenue
Arvinas had revenue of $41.90M in the quarter ending September 30, 2025, a decrease of -59.08%. This brings the company's revenue in the last twelve months to $312.30M, up 93.85% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$312.30M
Revenue Growth
+93.85%
P/S Ratio
2.75
Revenue / Employee
$726,279
Employees
430
Market Cap
760.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 211.09M |
| Maravai LifeSciences Holdings | 192.44M |
| Xencor | 150.13M |
| Arbutus Biopharma | 14.61M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
| Upstream Bio | 2.80M |
| YD Bio | 510.36K |
ARVN News
- 1 day ago - Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewsWire
- 2 months ago - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 2 months ago - Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 3 months ago - Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 3 months ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire